BHV-7000 Acute Treatment of Bipolar Mania

Last updated: March 4, 2025
Sponsor: Biohaven Therapeutics Ltd.
Overall Status: Completed

Phase

2/3

Condition

Bipolar Disorder

Mood Disorders

Treatment

Placebo

BHV-7000

Clinical Study ID

NCT06419582
BHV7000-204
  • Ages 18-75
  • All Genders

Study Summary

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  1. Participant must be voluntarily hospitalized for a current manic episode.

  2. Male and female participants 18 years to 75 years of age at the time of thescreening visit.

  3. Body Mass Index (BMI) must be ≥ 18 kg/m2 and ≤ 35 kg/m2.

  4. Meets DSM-5 criteria for bipolar disorder type I, with or without mixed features, asconfirmed by MINI interview with at least one well- defined prior mood episode (inaddition to the current episode). The most recent prior manic episode must haveoccurred in the last 2 years.

  5. Episode of mania must not exceed 12 weeks in duration.

  6. Participants must be able and willing to discontinue all other psychotropicmedications during the Screening Phase (e.g., antidepressant, antimanic,antipsychotic medications).

Exclusion

Key Exclusion Criteria:

  1. Rapid cycling is excluded as defined herein by subjects who have experienced ≥ 6distinct mood episodes in a year. Consecutive mood episodes must be demarcatedeither by a partial or full remission of at least 2 months' duration or by a switchto an episode of opposite polarity. Each manic or mixed episode must have lasted atleast 1 week, and each hypomanic episode must have lasted at least 4 days.

  2. Participants with a confirmed lifetime history of schizophrenia, psychoticdisorders, dementia, delirium, amnesia, neurodegenerative disease, traumatic braininjury with clinically significant sequalae, seizure disorder, or otherneurocognitive disorder. Previous diagnosis of psychotic spectrum disorders areallowable if the Investigator deems the diagnosis to be describing symptoms relatedto bipolar disorder.

  3. Any medical condition, based on the judgement of the Investigator, that wouldconfound the ability to adequately assess safety and efficacy outcome measures.

Study Design

Total Participants: 274
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 2/3
Study Start date:
May 28, 2024
Estimated Completion Date:
January 30, 2025

Connect with a study center

  • Pillar Clinical Research, LLC

    Bentonville, Arkansas 72712
    United States

    Site Not Available

  • WIRG

    Little Rock, Arkansas 72211
    United States

    Site Not Available

  • WRN

    Rogers, Arkansas 72758
    United States

    Site Not Available

  • Advanced Research Center, Inc.

    Anaheim, California 92805
    United States

    Site Not Available

  • CIT LA

    Bellflower, California 90706
    United States

    Site Not Available

  • ProScience Research Group

    Culver City, California 90230
    United States

    Site Not Available

  • Cenexel CNS

    Garden Grove, California 92845
    United States

    Site Not Available

  • Synergy San Diego

    Lemon Grove, California 91945
    United States

    Site Not Available

  • NRC Research Institute

    Orange, California 92868
    United States

    Site Not Available

  • CIT IE

    Riverside, California 92506
    United States

    Site Not Available

  • Cenexel CNS

    Torrance, California 90504
    United States

    Site Not Available

  • Cenexel - RCA

    Hollywood, Florida 33024
    United States

    Site Not Available

  • Segal Trials - Larkin Behavioral Health Services-Inpatient & Early Phase Site

    Hollywood, Florida 33021
    United States

    Site Not Available

  • LCC Medical Research Inst

    Miami, Florida 33126
    United States

    Site Not Available

  • Floridian Neuroscience Institute

    Miami Lakes, Florida 33016
    United States

    Site Not Available

  • Segal Trials - Miami Lakes Medical Research-Inpatient & Early Phase Site

    Miami Lakes, Florida 33016
    United States

    Site Not Available

  • Neuroscience Research Institute

    West Palm Beach, Florida 33407
    United States

    Site Not Available

  • Atlanta Center for Medical Research

    Atlanta, Georgia 30331
    United States

    Site Not Available

  • CenExel iResearch, LLC

    Decatur, Georgia 30030
    United States

    Site Not Available

  • CenExel iResearch, LLC

    Savannah, Georgia 31405
    United States

    Site Not Available

  • Pillar Clinical Research

    Chicago, Illinois 60641
    United States

    Site Not Available

  • Uptown Research Institute

    Chicago, Illinois 60640
    United States

    Site Not Available

  • CBH Health

    Gaithersburg, Maryland 20877
    United States

    Site Not Available

  • Precise Clinical Research

    Flowood, Mississippi 39232
    United States

    Site Not Available

  • Arch Clinical Trials

    Saint Louis, Missouri 63141
    United States

    Site Not Available

  • Hassman Research Institute

    Marlton, New Jersey 08053
    United States

    Site Not Available

  • RBA

    Staten Island, New York 10329
    United States

    Site Not Available

  • Midwest Clinical Research Center

    Dayton, Ohio 45417
    United States

    Site Not Available

  • NBCR

    North Canton, Ohio 44720
    United States

    Site Not Available

  • Community Clinical Research, Inc.

    Austin, Texas 78754
    United States

    Site Not Available

  • InSite Clinical Research, LLC

    DeSoto, Texas 75115
    United States

    Site Not Available

  • Pillar Clinical Research

    Richardson, Texas 75080
    United States

    Site Not Available

  • Pillar Clinical Research, LLC

    Richardson, Texas 75080
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.